Profile data is unavailable for this security.
About the company
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
- Revenue in USD (TTM)94.19bn
- Net income in USD26.80bn
- Incorporated1887
- Employees138.10k
- LocationJohnson & JohnsonOne Johnson & Johnson PlazaNEW BRUNSWICK 08933United StatesUSA
- Phone+1 (732) 524-2455
- Fax+1 (732) 214-0332
- Websitehttps://www.jnj.com/
Mergers & acquisitions
| Acquired company | JNJ:NYQ since announced | Transaction value |
|---|---|---|
| Halda Therapeutics OpCo Inc | 24.04% | 3.05bn |
| Protagonist Therapeutics Inc | 27.19% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc | 11.72bn | 3.68bn | 117.03bn | 6.10k | 32.41 | 6.76 | 30.19 | 9.98 | 14.23 | 14.23 | 45.38 | 68.20 | 0.4978 | 1.19 | 6.34 | 1,921,853.00 | 15.60 | 14.06 | 19.02 | 16.67 | 86.28 | 87.35 | 31.35 | 26.28 | 2.00 | -- | 0.00 | 0.00 | 11.66 | 21.50 | -114.80 | -- | 45.11 | -- |
| Bristol-Myers Squibb Co | 48.19bn | 7.05bn | 122.00bn | 34.10k | 17.33 | -- | 11.18 | 2.53 | 3.46 | 3.46 | 23.63 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 72.62 | 76.32 | 14.64 | 8.34 | -- | 16.84 | -- | -- | -0.2195 | 2.54 | 178.83 | -- | -- | 0.658 |
| Pfizer Inc | 62.58bn | 7.75bn | 157.66bn | 81.00k | 20.46 | -- | 11.33 | 2.52 | 1.36 | 1.36 | 10.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 75.81 | 69.03 | 12.44 | 19.52 | -- | 9.38 | -- | -- | -1.65 | 8.48 | -3.42 | 3.16 | -- | 2.50 |
| Gilead Sciences Inc | 29.44bn | 8.51bn | 193.30bn | 17.60k | 22.97 | 8.55 | 23.01 | 6.57 | 6.78 | 6.78 | 23.46 | 18.23 | 0.499 | 2.05 | 6.31 | -- | 14.42 | 8.03 | 18.05 | 9.82 | 78.84 | 78.01 | 28.91 | 18.13 | 1.31 | 36.91 | -- | 73.41 | 2.40 | 3.58 | 1,672.92 | 133.35 | -- | 3.04 |
| Amgen Inc | 36.75bn | 7.71bn | 197.40bn | 28.00k | 25.76 | 22.82 | 18.87 | 5.37 | 14.23 | 14.23 | 67.84 | 16.06 | 0.4029 | 1.48 | 4.49 | -- | 8.45 | 7.90 | 11.52 | 10.18 | 73.30 | 74.68 | 20.98 | 20.55 | 0.8958 | 18.59 | 0.8631 | 72.99 | 9.95 | 7.65 | 88.53 | 1.20 | 25.03 | 8.27 |
| Merck & Co Inc | 65.01bn | 18.25bn | 296.13bn | 75.00k | 16.40 | -- | 15.84 | 4.56 | 7.28 | 7.28 | 25.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 78.55 | 75.41 | 28.09 | 21.08 | -- | 22.68 | -- | -- | 1.31 | 9.38 | 6.64 | 32.21 | -- | 6.01 |
| AbbVie Inc | 59.64bn | 2.35bn | 390.40bn | 55.00k | 166.67 | -- | 36.28 | 6.55 | 1.33 | 1.33 | 33.68 | -1.49 | 0.4302 | 3.66 | 4.92 | 1,084,436.00 | 1.73 | 5.44 | 2.46 | 7.09 | 71.16 | 68.89 | 4.02 | 13.73 | 0.5992 | 7.60 | 1.04 | 134.96 | 3.71 | 11.11 | -12.07 | -11.58 | 12.03 | 8.00 |
| Johnson & Johnson | 94.19bn | 26.80bn | 580.30bn | 138.10k | 21.81 | -- | 21.35 | 6.16 | 11.05 | 11.05 | 38.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 67.92 | 69.10 | 28.46 | 20.70 | -- | -- | -- | -- | 6.05 | 2.67 | 90.56 | 13.21 | -- | 5.49 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jan 2026 | 243.46m | 10.11% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 132.21m | 5.49% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 129.42m | 5.37% |
| Geode Capital Management LLCas of 30 Sep 2025 | 56.22m | 2.33% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2025 | 35.93m | 1.49% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 31.93m | 1.33% |
| State Farm Investment Management Corp.as of 30 Sep 2025 | 31.59m | 1.31% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 25.90m | 1.08% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 25.40m | 1.05% |
| BlackRock Investment Management (UK) Ltd.as of 30 Sep 2025 | 25.36m | 1.05% |
